血小板膜糖蛋白CD62P、CD63對進(jìn)展性腦梗死的早期診斷作用的研究.pdf

1、山西醫(yī)科大學(xué)碩士學(xué)位論文血小板膜糖蛋白CD62P、CD63對進(jìn)展性腦梗死的早期診斷作用的研究姓名：陳智玲申請學(xué)位級別：碩士專業(yè)：神經(jīng)病學(xué)指導(dǎo)教師：馬靜萍20070420山西醫(yī)科大學(xué)磺士學(xué)位論文AstudyontheearlydiagnosevalueofthebloodplateletmembraneglycoproteinCD62PCD63toprogressivecerebralinfarctionAbstractObjective

2、：bymeasuringtheexpressionrateofthebloodplateletmembraneglycoproteinCD62ECD63anddrawingtheROCcurvetoevaluatethediagnosisvaluetoprogressivecerebralinfarctionMaterialandmethods：wecollected103cases，agedfrom30to80fromthe1“att

3、iliatedhospitalofShanxiMedicalUniversityfromMarch2006toDecember2006，anddividedthemintotwogroups：progressivecerebralinfarction(n=35)，non—progressivecerebralinfarction(n68)Thediagnosisisaccordingtothecriteriarevisedbythe44

4、CerebrovascularDiseaseConferenceTheheadCTandMRlwereconductedtomakesurethatthefoeiwerenewThediagnosisoftheprogressivecerebralinfarctionis：theconditionsstillaggravatethroughtheoneweekconventionaltherapyafter6hoursoftheonse

5、tandfitsoneofthefollowingrules：(1)musclescrengthdroped1leverormoreontheparalysedsidecomparedwiththatofthebeginningofhospitalization(2)NeurologicalfunctionimpairmentScoreincreased8orabove；(3)Tuleoutthepossibilityofcerebra

6、lhemorrhagicbyCTaftertheconditions’worseningTheexclusioncriteriawere：(1)hemorrhagiccerebrovasulardiseases；(2)severecerebralinfarction；(3)patientswithseriousdiseasesinheart，lung，kidneyliverandSOon；(4)patientswhohadusedant

7、i—coagulationdrugsorplateletaggregationinhibitorbeforethediseaseonsetThecontrolgroupincluded68caseswhowerenon—progressivecerebralinfarctionWeperformeddetailedphysicalexaminationforselectedpatientsandrecordedtheirresultso

8、fthescoreaccordingtothecriteriapassedbythe4thCerebrovascularDiseaseConference(seetheattachedlistl)Weobtained09mlulnarveinbloodfromallthepatients。andaddeditintoplastictubecontainingO1ml38％criticacidtopreventbloodclottingt

9、henWemarkedthesequencenumberforcytometrytubeIntheoddernumbertubesweadded20la1mouseanti—personlgGmarkedbyFITC，20“1mouseanti—personIgGmarkedbyPE。20ulanti—CD61antibodymarkedbyPerCPasnegativecontroltube；intheeven—numberedtub

10、esweadded20H1anti—CD61antibodymarkedbyPerCE20ulanti—CD62anti—bodymarkedbyPE20“l(fā)anti—CD63antibodymarkedbyFITCastesttubes；thenadded5p1anti—conglulationbloodintheflowcytometrytubesrespectivelymixedfullyprotectedfromlightfor

11、15minutes；thentookitoutandaddedl％paraformaldehydesolutionforfixationanalyzedontheFCMWeexaminedthepatientsonthedailybasesandrecordedtheneurologicalfunctionimpairmentscoresResult：thedifferenceofexpressionratesofCD62pandCD6